Congestive heart failure: what should be the initial therapy and why?

Area of Science:

• Cardiology
• Pharmacology
• Heart Failure Research

Background:

• Left ventricular systolic dysfunction triggers neurohormonal activation, leading to progressive ventricular remodeling and heart failure.
• Both symptomatic and asymptomatic patients with left ventricular systolic dysfunction exhibit activation of the renin-angiotensin-aldosterone and sympathetic nervous systems.
• Angiotensin and adrenergic system activation negatively impacts hemodynamics, promotes myocyte hypertrophy and fibroblast growth, and can cause myocyte necrosis and apoptosis.

Purpose of the Study:

• To outline pharmacologic strategies for managing left ventricular systolic dysfunction.
• To emphasize the importance of therapies that prevent ventricular remodeling and improve prognosis.
• To review current treatment options for heart failure.

Main Methods:

• Review of existing studies on pharmacologic interventions for systolic heart failure.
• Analysis of the efficacy of ACE inhibitors, ARBs, digitalis, diuretics, beta-blockers, and spironolactone.
• Consideration of risk factor modification for patients with heart failure secondary to ischemic heart disease.

Main Results:

• ACE inhibitors improve exercise tolerance and decrease treatment failure in symptomatic patients, and reduce mortality.
• Angiotensin II receptor blockers (ARBs) offer similar survival benefits to ACE inhibitors but may be better tolerated.
• Long-term adrenergic inhibition with beta-blockers, combined with ACE inhibitors, attenuates remodeling, improves function, and enhances survival in symptomatic systolic heart failure.

Conclusions:

• Initial pharmacotherapy for systolic heart failure should prioritize maximal tolerated doses of ACE inhibitors or ARBs if ACE inhibitors are not tolerated.
• Diuretics should be used judiciously for symptom relief, not long-term therapy.
• Combination therapy including ACE inhibitors/ARBs, potentially with digoxin, hydralazine/isosorbide dinitrate, diuretics, and spironolactone, alongside risk factor modification, is crucial for managing systolic heart failure and improving patient outcomes.